Skip to main content
Monday, November 16, 2026Nov 16

FDA review spotlights heart risk of diabetes pill

By MATTHEW PERRONE

AP Business Writer

WASHINGTON – A review by federal health scientists reinforces potential ties between the diabetes pill Avandia and heart attack and death, opening the door for government action, including a possible withdrawal of the once blockbuster drug.

The Food and Drug Administration posted an exhaustive 700-page review of the GlaxoSmithKline drug online Friday ahead of a meeting next week to review the safety of Avandia, which is used by hundreds of thousands of diabetics in the U.S.

FDA scientists reviewed dozens of studies of Avandia, including one which Glaxo has pointed to as proof of the drug’s safety. But an FDA reviewer said the study was plagued by “serious flaws” and actually supports the case against Avandia.